Researchers in the United States have reported promising preclinical findings for an experimental vaccine that combines protection against seasonal influenza, COVID-19 and respiratory syncytial virus (RSV) into a single annual injection. The study, published in Science Advances, represents an important step towards simplifying immunisation strategies for respiratory diseases that continue to place substantial pressure on healthcare systems worldwide.
The research comes at a time when influenza viruses, SARS-CoV-2 and RSV frequently circulate during the same respiratory virus season, contributing to increased hospital admissions, particularly among older adults and individuals with underlying medical conditions.
A unified approach to seasonal respiratory protection
The investigational vaccine was developed using a nanoparticle-based platform designed to deliver proteins from multiple viruses simultaneously. Unlike messenger RNA (mRNA) vaccines, this approach relies on purified viral proteins attached to specialised nanoparticles, allowing the immune system to recognise several pathogens after a single vaccination.
Scientists incorporated proteins from influenza viruses, SARS-CoV-2 and RSV into one formulation, together with immune-enhancing compounds intended to strengthen the body's protective response.
Preclinical experiments involving mice, ferrets and cotton rats demonstrated that the combined vaccine generated antibody responses comparable to those achieved by vaccines targeting each virus individually. Importantly, researchers found no evidence that combining the three components reduced the immune response against any of the viruses studied.
Addressing the challenge of vaccine uptake
Public health experts have consistently highlighted that many eligible individuals do not receive all recommended seasonal respiratory vaccines. Separate vaccinations for influenza, COVID-19 and RSV may contribute to lower uptake due to convenience, scheduling and access barriers.
The investigators suggest that a single annual vaccine could simplify immunisation programmes and potentially improve vaccination coverage, particularly among older populations, who remain at the highest risk of severe respiratory illness.
According to the researchers, improving adherence to vaccination recommendations may help reduce hospitalisations and lessen the burden on healthcare services during peak respiratory virus seasons.
Flexible vaccine technology
The vaccine candidate uses a nanoparticle platform known as CoPoP, which enables several viral proteins to be incorporated into one formulation. This flexibility could allow scientists to update vaccine components as circulating viruses evolve or even expand the platform to include protection against additional respiratory pathogens in the future.
The same technological platform has previously been investigated in clinical trials for a COVID-19 vaccine candidate, providing researchers with experience regarding its manufacturing and potential application.
Encouraging findings, but human studies remain essential
Although the laboratory and animal results are encouraging, the researchers emphasise that these findings do not demonstrate effectiveness in humans. Clinical trials will be necessary to determine the vaccine's safety, optimal dosage and protective efficacy across different age groups, including older adults and people with weakened immune systems.
The investigators also noted that additional studies are required to evaluate whether subtle interactions between the different vaccine components might influence long-term immune responses under various vaccination schedules.
Potential implications for future vaccination programmes
If future clinical trials confirm these early findings, a combined vaccine could represent an important advance in preventive medicine by reducing the number of separate injections required each year while maintaining protection against three of the most significant seasonal respiratory viruses.
Health authorities continue to recommend that eligible individuals receive currently approved vaccines against influenza, COVID-19 and RSV according to national immunisation guidelines, as the experimental combination vaccine remains under development and is not yet available for clinical use.